Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model

Pawel Mroz, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species that eventually cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, recognition of tumor-specific antigens, and induction of heat-shock proteins, while the three commonest cancer therapies (surgery, chemotherapy and radiotherapy) all tend to suppress the immune system. Like many other immunotherapies, the extent of the immune response after PDT tends to depend on the antigenicity of the particular tumor, or in other words, whether the tumor contains proteins with the correct characteristics to provide peptides that can bind to MHC class I molecules and provide a target for cytolytic T lymphocytes. We have described certain mouse tumors containing defined or naturally occurring tumor associated antigens that respond particularly well to PDT, and potent immune responses capable of destroying distant untreated tumors can be induced. In this report we address the induction of immunity after PDT of the DBA2 mastocytoma known as P815. This tumor was the first mouse tumor to be shown to possess a tumor-rejection antigen capable of being recognized by cytotoxic T-cells.

Original languageEnglish (US)
Title of host publicationBiophotonics and Immune Responses III
Volume6857
DOIs
StatePublished - May 15 2008
EventBiophotonics and Immune Responses III - San Jose, CA, United States
Duration: Jan 21 2008Jan 21 2008

Other

OtherBiophotonics and Immune Responses III
CountryUnited States
CitySan Jose, CA
Period1/21/081/21/08

Fingerprint

Photodynamic therapy
Tumors
Antigens
T-cells
Proteins
Photosensitizers
Chemotherapy
Immune system
Radiotherapy
Cell death
Surgery
Peptides
Lighting
Cells

Keywords

  • Cytotoxic T cells
  • Mastocytoma
  • Photodynamic therapy
  • Tumor-associated antigen

Cite this

Mroz, P., & Hamblin, M. R. (2008). Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model. In Biophotonics and Immune Responses III (Vol. 6857). [685706] https://doi.org/10.1117/12.764922

Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model. / Mroz, Pawel; Hamblin, Michael R.

Biophotonics and Immune Responses III. Vol. 6857 2008. 685706.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mroz, P & Hamblin, MR 2008, Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model. in Biophotonics and Immune Responses III. vol. 6857, 685706, Biophotonics and Immune Responses III, San Jose, CA, United States, 1/21/08. https://doi.org/10.1117/12.764922
Mroz P, Hamblin MR. Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model. In Biophotonics and Immune Responses III. Vol. 6857. 2008. 685706 https://doi.org/10.1117/12.764922
Mroz, Pawel ; Hamblin, Michael R. / Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model. Biophotonics and Immune Responses III. Vol. 6857 2008.
@inproceedings{3f0e814a77624e56b771b031fcfa3acd,
title = "Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model",
abstract = "Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species that eventually cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, recognition of tumor-specific antigens, and induction of heat-shock proteins, while the three commonest cancer therapies (surgery, chemotherapy and radiotherapy) all tend to suppress the immune system. Like many other immunotherapies, the extent of the immune response after PDT tends to depend on the antigenicity of the particular tumor, or in other words, whether the tumor contains proteins with the correct characteristics to provide peptides that can bind to MHC class I molecules and provide a target for cytolytic T lymphocytes. We have described certain mouse tumors containing defined or naturally occurring tumor associated antigens that respond particularly well to PDT, and potent immune responses capable of destroying distant untreated tumors can be induced. In this report we address the induction of immunity after PDT of the DBA2 mastocytoma known as P815. This tumor was the first mouse tumor to be shown to possess a tumor-rejection antigen capable of being recognized by cytotoxic T-cells.",
keywords = "Cytotoxic T cells, Mastocytoma, Photodynamic therapy, Tumor-associated antigen",
author = "Pawel Mroz and Hamblin, {Michael R.}",
year = "2008",
month = "5",
day = "15",
doi = "10.1117/12.764922",
language = "English (US)",
isbn = "9780819470324",
volume = "6857",
booktitle = "Biophotonics and Immune Responses III",

}

TY - GEN

T1 - Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model

AU - Mroz, Pawel

AU - Hamblin, Michael R.

PY - 2008/5/15

Y1 - 2008/5/15

N2 - Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species that eventually cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, recognition of tumor-specific antigens, and induction of heat-shock proteins, while the three commonest cancer therapies (surgery, chemotherapy and radiotherapy) all tend to suppress the immune system. Like many other immunotherapies, the extent of the immune response after PDT tends to depend on the antigenicity of the particular tumor, or in other words, whether the tumor contains proteins with the correct characteristics to provide peptides that can bind to MHC class I molecules and provide a target for cytolytic T lymphocytes. We have described certain mouse tumors containing defined or naturally occurring tumor associated antigens that respond particularly well to PDT, and potent immune responses capable of destroying distant untreated tumors can be induced. In this report we address the induction of immunity after PDT of the DBA2 mastocytoma known as P815. This tumor was the first mouse tumor to be shown to possess a tumor-rejection antigen capable of being recognized by cytotoxic T-cells.

AB - Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species that eventually cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, recognition of tumor-specific antigens, and induction of heat-shock proteins, while the three commonest cancer therapies (surgery, chemotherapy and radiotherapy) all tend to suppress the immune system. Like many other immunotherapies, the extent of the immune response after PDT tends to depend on the antigenicity of the particular tumor, or in other words, whether the tumor contains proteins with the correct characteristics to provide peptides that can bind to MHC class I molecules and provide a target for cytolytic T lymphocytes. We have described certain mouse tumors containing defined or naturally occurring tumor associated antigens that respond particularly well to PDT, and potent immune responses capable of destroying distant untreated tumors can be induced. In this report we address the induction of immunity after PDT of the DBA2 mastocytoma known as P815. This tumor was the first mouse tumor to be shown to possess a tumor-rejection antigen capable of being recognized by cytotoxic T-cells.

KW - Cytotoxic T cells

KW - Mastocytoma

KW - Photodynamic therapy

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=43249092616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249092616&partnerID=8YFLogxK

U2 - 10.1117/12.764922

DO - 10.1117/12.764922

M3 - Conference contribution

SN - 9780819470324

VL - 6857

BT - Biophotonics and Immune Responses III

ER -